A study published recently in PLOS One suggests that therapy may, in fact, play an important role in psilocybin-assisted therapy for major depressive disorder.
In a study of 24 participants with MDD, those who reported stronger alliance, or “sense of collaboration between patient and client,” with their therapist were more likely to show improvements in their depression scores after two psilocybin dosing sessions.
Stronger ratings of therapeutic alliance during the study’s final preparation session were correlated with improved depression scores for 12 months after the study.
Read moreAre psychedelics an antidote to pessimism?
Research indicates that psychedelic therapy can improve mental health outcomes by addressing the pessimism bias.
Read moreCybin, a biotech company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of depression.
CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.
The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.
Read moreThis ketamine trial for resistant depression shows positive results.
The study is the largest to date comparing generic ketamine with placebo in treating severe depression.
Read moreKeep reading for the history of the chemical imbalance theory, how a study last year tried to debunk it, and how that study is now seen to be flawed.
Read moreThe psychedelic therapy ketamine is said to help many people, but some like this author have scary experiences.
Read more